[Clinical considerations on a new synthetic compound with antipyretic and anticatarrhal action].
A Broncaspin suspension was administered for an average of 6-7 days (1/2 teaspoonful twice a day to patients up to 3 yr old; 1 teaspoonful twice a day to those over 3) in the treatment of acute febrile diseases of the upper airways in 16 male and 14 female children aged 5 months to 5 and 3/12 yr. Satisfactory results were obtained in all cases.
D001241:Aspirin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001991:Bronchitis / Q000188:drug therapy; D002675:Child, Preschool; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009304:Nasopharyngitis / Q000188:drug therapy; D010031:Otitis / Q000188:drug therapy; D010612:Pharyngitis / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D014136:Tracheitis / Q000188:drug therapy
D001241:Aspirin; C023557:guacetisal
Considerazioni cliniche su un nuovo composto di sintesi ad azione antipiretica ed anticatarrale.